Kangmei Pharmaceutical Co Ltd (600518):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Kangmei Pharmaceutical Co Ltd (600518) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8057
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kangmei Pharmaceutical Co Ltd (Kangmei) is a manufacturer and distributor of herbal medicine. The company provides herbal raw materials and preparations. Kangmei products include Chinese herbal medicine, bottled single product, hong mei life, xinkaihe senate, chinese medicine derived, medicine, chemical drugs and ju huang tea among others. It provides chemical drugs such as clarithromycin dispersible tablets, doxazosin mesylate tablets, propiverine hydrochloride tablets, and paracetamol and pseudoephedrine hydrochloride tablets. The company also offers Xinkaihe warm tea, Ginkgo thirty-seven hawthorn polyphenol capsules, Propolis, McKinley card Calcium Iron zinc and selenium chewable tablets, and Happiness red Luzhou nourishing Okuma. It operates in Beijing, Shanghai and Hong Kong. Kangmei is headquartered in Shenzhen, Guangdong, China.

Kangmei Pharmaceutical Co Ltd (600518) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kangmei Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Kangmei Pharma To Acquire Three Hospitals In China For US$82 Million 12
Venture Financing 13
Twist Bioscience Raises Additional USD27 Million in Venture Financing 13
Partnerships 15
Kangmei Pharma Enters into Agreement with BGI Genomics 15
Equity Offering 16
Kangmei Pharma Raises USD1.3 Billion in Private Placement of Shares 16
Kangmei Pharma Plans For Private Placement Of Shares For USD972.4 Million 17
Debt Offering 18
Kangmei Pharma Raises USD154 Million in Public Offering of 7% Notes Due 2021 18
Kangmei Pharma Plans to Raise USD159.21 Million in Public Offering of Bonds 19
Kangmei Pharma Raises USD236.9 Million in Public Offering of 5.38% 2018 First Tranche Notes Due 2018 20
Kangmei Pharma Raises USD454.1 Million in Private Placement of Bonds 21
Kangmei Pharma Raises USD304.7 Million in Public Offering of Third Tranche of 5.47% Notes Due 2022 22
Kangmei Pharma Raises USD300 Million in Public Offering of Second Tranche of 5.29% Notes Due 2022 23
Kangmei Pharma to Raise USD1.6 Billion in Public Offering of Notes 24
Kangmei Pharma Raises USD220.3 Million in Public Offering of Debentures 25
Kangmei Pharma Raises USD369 Million in First Tranche of Public Offering of 3.28% Debentures Due 2017 26
Kangmei Pharma to Raise up to USD391 Million in Private Placement of Bonds 27
Acquisition 28
Kangmei Pharma to Acquire 80% Stake in Huizhou-Based Pharmaceutical Company for USD3.18 million 28
Kangmei Pharma Plans to Acquire Pharmaceutical Company for USD21 Million 29
Kangmei Pharma to Acquire Chongqing Ruitai Pharma for USD12.5 Million 30
Kangmei Pharma to Acquire 80% Stake in Guangdong Xin’ao Pharma for USD9 Million 31
Kangmei Pharma to Acquire Shenzhen Ieman Pharma for USD3.5 Million 32
Kangmei Pharmaceutical Co Ltd – Key Competitors 33
Kangmei Pharmaceutical Co Ltd – Key Employees 34
Kangmei Pharmaceutical Co Ltd – Locations And Subsidiaries 35
Head Office 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kangmei Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Kangmei Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kangmei Pharma To Acquire Three Hospitals In China For US$82 Million 12
Twist Bioscience Raises Additional USD27 Million in Venture Financing 13
Kangmei Pharma Enters into Agreement with BGI Genomics 15
Kangmei Pharma Raises USD1.3 Billion in Private Placement of Shares 16
Kangmei Pharma Plans For Private Placement Of Shares For USD972.4 Million 17
Kangmei Pharma Raises USD154 Million in Public Offering of 7% Notes Due 2021 18
Kangmei Pharma Plans to Raise USD159.21 Million in Public Offering of Bonds 19
Kangmei Pharma Raises USD236.9 Million in Public Offering of 5.38% 2018 First Tranche Notes Due 2018 20
Kangmei Pharma Raises USD454.1 Million in Private Placement of Bonds 21
Kangmei Pharma Raises USD304.7 Million in Public Offering of Third Tranche of 5.47% Notes Due 2022 22
Kangmei Pharma Raises USD300 Million in Public Offering of Second Tranche of 5.29% Notes Due 2022 23
Kangmei Pharma to Raise USD1.6 Billion in Public Offering of Notes 24
Kangmei Pharma Raises USD220.3 Million in Public Offering of Debentures 25
Kangmei Pharma Raises USD369 Million in First Tranche of Public Offering of 3.28% Debentures Due 2017 26
Kangmei Pharma to Raise up to USD391 Million in Private Placement of Bonds 27
Kangmei Pharma to Acquire 80% Stake in Huizhou-Based Pharmaceutical Company for USD3.18 million 28
Kangmei Pharma Plans to Acquire Pharmaceutical Company for USD21 Million 29
Kangmei Pharma to Acquire Chongqing Ruitai Pharma for USD12.5 Million 30
Kangmei Pharma to Acquire 80% Stake in Guangdong Xin'ao Pharma for USD9 Million 31
Kangmei Pharma to Acquire Shenzhen Ieman Pharma for USD3.5 Million 32
Kangmei Pharmaceutical Co Ltd, Key Competitors 33
Kangmei Pharmaceutical Co Ltd, Key Employees 34

List of Figures
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kangmei Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kangmei Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Kangmei Pharmaceutical Co Ltd (600518):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ALLETE, Inc.:企業の戦略・SWOT・財務情報
    ALLETE, Inc. - Strategy, SWOT and Corporate Finance Report Summary ALLETE, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Strukton Groep NV:企業の戦略・SWOT・財務情報
    Strukton Groep NV - Strategy, SWOT and Corporate Finance Report Summary Strukton Groep NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Medpace Inc (MEDP):企業の財務・戦略的SWOT分析
    Summary Medpace Inc (Medpace), a subsidiary of Medpace Holdings Inc is a contract research organization that develops research based drug and medical device. The organization provides services such as medical affairs, regulatory affairs and medical writing, clinical monitoring, clinical trial manage …
  • Benesse Holdings, Inc. (9783):企業の財務・戦略的SWOT分析
    Benesse Holdings, Inc. (9783) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Reed’s, Inc.:企業の戦略・SWOT・財務情報
    Reed's, Inc. - Strategy, SWOT and Corporate Finance Report Summary Reed's, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Molecular Partners AG (MOLN):企業の財務・戦略的SWOT分析
    Summary Molecular Partners AG (Molecular Partners) is a clinical stage biopharmaceutical company that develops biological drugs. The company offers advanced small protein therapies such as abicipar, a designed ankyrin repeat protein based anti-angiogenic drug developed for diabetic macular edema and …
  • Pharmadax Inc (4191):製薬・医療:M&Aディール及び事業提携情報
    Summary Pharmadax Inc (Pharmadax) is a drug development and generic specialty pharmaceutical company. The company develops modified release generics in various therapeutic segments. It offers products such as glyburide, quetiapine fumarate ER and metoprolol succinate ER. Pharmadax provides in the pr …
  • Questerre Energy Corp (QEC):企業の財務・戦略的SWOT分析
    Summary Questerre Energy Corp (Questerre) is an independent oil and gas exploration and development company that acquires, explores, develops and produces unconventional oil and gas properties. The company’s unconventional properties include tight oil, shale oil and shale gas. It has base production …
  • Sompo Japan Nipponkoa Holdings, Inc.:企業の戦略・SWOT・財務情報
    Sompo Japan Nipponkoa Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Sompo Japan Nipponkoa Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • QinetiQ Group plc:戦略・SWOT・企業財務分析
    QinetiQ Group plc - Strategy, SWOT and Corporate Finance Report Summary QinetiQ Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Sims Metal Management Ltd:企業の戦略・SWOT・財務分析
    Sims Metal Management Ltd - Strategy, SWOT and Corporate Finance Report Summary Sims Metal Management Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Idorsia Pharmaceutical Ltd (IDIA):製薬・医療:M&Aディール及び事業提携情報
    Summary Idorsia Pharmaceutical Ltd (Idorsia) is a manufacturer and developer of medicine that discovers, develops various therapies. The company provides pipeline portfolio such as investigational candidates targeted at the treatment of resistant hypertension, chronic insomnia, vasospasm, and system …
  • Nobel Biocare Services AG:企業の戦略的SWOT分析
    Nobel Biocare Services AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Konsortium Transnasional Berhad:企業の戦略・SWOT・財務情報
    Konsortium Transnasional Berhad - Strategy, SWOT and Corporate Finance Report Summary Konsortium Transnasional Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Mobidiag Ltd:企業の製品パイプライン分析
    Summary Mobidiag Ltd (Mobidiag) operates as a biotechnology company that develops and markets products for molecular diagnosis of infectious diseases and test kits. The company's products portfolio includes Novodiag, Amplidiag, and Prove-it. Its Amplidiag is a diagnostic test for high-volume screeni …
  • ToolGen Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary ToolGen Inc (ToolGen) is a genome editing company that concentrates on translating the genetic knowledge into transformative products for biomedicine and agriculture. The company creates intellectual property rights for essential tools and technologies for editing the genetic information in …
  • BT Group plc:企業の戦略・SWOT・財務情報
    BT Group plc - Strategy, SWOT and Corporate Finance Report Summary BT Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Biomerica Inc (BMRA):企業の製品パイプライン分析
    Summary Biomerica, Inc. (Biomerica) develops, manufactures, and markets medical diagnostic products used for the early detection and monitoring of chronic diseases and medical conditions. The company’s diagnostic test kits used to analyze blood, urine and fecal specimens of the patient to diagnose v …
  • BW Group Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary BW Group Ltd (BW Group) formerly Bergesen Worldwide Limited, is an oil and gas company which provides maritime services. The company offers oil and gas shipping and others related services. It offers environmental technologies, floating gas infrastructure, and deepwater production services. …
  • High Peak Royalties Ltd (HPR):石油・ガス:M&Aディール及び事業提携情報
    Summary High Peak Royalties Limited (High Peak) is a leading utility company that builds a portfolio of diversified resource royalties with projects in exploration, pre-production and producing phases. It assesses a regular flow of potential royalty investments across the resources sector. The compa …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆